A detailed history of Geode Capital Management, LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Geode Capital Management, LLC holds 3,313,158 shares of ABUS stock, worth $12.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,313,158
Previous 2,958,887 11.97%
Holding current value
$12.8 Million
Previous $7.63 Million 34.12%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$2.52 - $3.63 $892,762 - $1.29 Million
354,271 Added 11.97%
3,313,158 $10.2 Million
Q1 2024

May 13, 2024

BUY
$2.26 - $2.92 $319,093 - $412,280
141,192 Added 5.01%
2,958,887 $7.63 Million
Q4 2023

Feb 13, 2024

BUY
$1.69 - $2.54 $203,832 - $306,351
120,611 Added 4.47%
2,817,695 $7.04 Million
Q3 2023

Nov 13, 2023

BUY
$1.9 - $2.27 $188,020 - $224,634
98,958 Added 3.81%
2,697,084 $5.48 Million
Q2 2023

Aug 11, 2023

BUY
$2.24 - $3.06 $694,877 - $949,251
310,213 Added 13.56%
2,598,126 $5.98 Million
Q1 2023

May 15, 2023

BUY
$2.23 - $3.1 $349,318 - $485,599
156,645 Added 7.35%
2,287,913 $6.93 Million
Q4 2022

Feb 13, 2023

BUY
$1.91 - $2.85 $231,927 - $346,069
121,428 Added 6.04%
2,131,268 $4.97 Million
Q3 2022

Nov 14, 2022

BUY
$1.88 - $2.88 $422,620 - $647,418
224,798 Added 12.59%
2,009,840 $3.84 Million
Q2 2022

Aug 12, 2022

BUY
$1.98 - $3.17 $109,026 - $174,552
55,064 Added 3.18%
1,785,042 $4.84 Million
Q1 2022

May 13, 2022

BUY
$2.42 - $3.98 $146,056 - $240,208
60,354 Added 3.61%
1,729,978 $5.16 Million
Q4 2021

Feb 11, 2022

BUY
$3.11 - $4.61 $401,790 - $595,579
129,193 Added 8.39%
1,669,624 $6.49 Million
Q3 2021

Nov 12, 2021

BUY
$2.65 - $4.62 $672,498 - $1.17 Million
253,773 Added 19.72%
1,540,431 $6.61 Million
Q2 2021

Aug 13, 2021

BUY
$2.5 - $3.51 $1.88 Million - $2.64 Million
752,076 Added 140.68%
1,286,658 $3.9 Million
Q1 2021

May 12, 2021

BUY
$3.14 - $4.84 $417,403 - $643,386
132,931 Added 33.1%
534,582 $1.78 Million
Q4 2020

Feb 12, 2021

BUY
$2.76 - $4.97 $58,716 - $105,731
21,274 Added 5.59%
401,651 $1.43 Million
Q3 2020

Nov 13, 2020

BUY
$1.75 - $6.2 $117,857 - $417,551
67,347 Added 21.51%
380,377 $1.19 Million
Q2 2020

Aug 13, 2020

BUY
$0.91 - $2.36 $186,216 - $482,936
204,634 Added 188.78%
313,030 $569,000
Q1 2020

May 14, 2020

SELL
$1.01 - $3.42 $19,308 - $65,380
-19,117 Reduced 14.99%
108,396 $109,000
Q4 2019

Feb 13, 2020

BUY
$0.87 - $2.89 $45,576 - $151,398
52,387 Added 69.73%
127,513 $354,000
Q3 2019

Nov 12, 2019

SELL
$1.34 - $2.4 $2,102 - $3,765
-1,569 Reduced 2.05%
75,126 $114,000
Q2 2019

Aug 14, 2019

SELL
$1.46 - $4.44 $271,990 - $827,149
-186,295 Reduced 70.84%
76,695 $159,000
Q1 2019

May 14, 2019

BUY
$3.41 - $4.57 $92,267 - $123,655
27,058 Added 11.47%
262,990 $941,000
Q4 2018

Feb 13, 2019

BUY
$3.5 - $9.66 $178,944 - $493,886
51,127 Added 27.67%
235,932 $903,000
Q3 2018

Nov 13, 2018

BUY
$7.85 - $12.35 $478,983 - $753,559
61,017 Added 49.29%
184,805 $1.75 Million
Q2 2018

Aug 14, 2018

BUY
$5.0 - $7.35 $547,600 - $804,972
109,520 Added 767.59%
123,788 $903,000
Q4 2017

Feb 13, 2018

SELL
$4.45 - $7.7 $57,169 - $98,921
-12,847 Reduced 47.38%
14,268 $72,000
Q2 2017

Aug 14, 2017

BUY
N/A
27,115
27,115 $97,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $580M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.